Four-S Fortnightly PharmaHealth Track - Newsletter on Indian Healthcare Industry - Issue 8

  • ID: 2204706
  • July 2012
  • Region: India
  • 11 Pages
  • Four-S Services
1 of 3

This issue covers 9th - 21st July 2012.

Fortnightly update on the Indian Healthcare Industry

In the Spotlight

Unfair practices: Pharma cos GlaxoSmithkline, Pfizer, Johnson & Johnson and others fined $13 bn in 4 years In the past four years, leading members of Big Pharma like GlaxoSmithkline, Pfizer, Johnson & Johnson, AstraZeneca, Merck, Abbot, Eli Lilly and Allergen have paid about $13 billion in fines to settle charges of misleading marketing, promising what drugsdon't do, bribing doctors to get their drugs prescribed, causing sometimes fatal side-effects, and other crimes. The patients targeted by them ranged from children to dementia afflicted senior citizens. An analysis of their total revenues and the income from the drugs they are charged with shows that while huge, the fines are at best slaps on the wrist - their jaw-dropping revenues far outweigh the penalties. GlaxoSmithKline was fined $3 billion by the US justice department for marketing drugs for unapproved uses, paying kickbacks to doctors and Medicare system, downplaying known risks of certain drugs. Pfizer, the world's biggest pharma company with annual revenue of over $67 billion last year, READ MORE >

Note: Product cover images may vary from those shown
2 of 3

News of the fortnight

Investment Activity

News Update

Stock Market Updates

Peer Benchmarking

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.


If you have a more general question about our products please try our



Our Clients

  • Pfizer, Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S